Elanco Animal Health (ELAN): Assessing Valuation After a Strong Share Price Recovery

Simply Wall St.12-17 05:19

Elanco Animal Health (ELAN) has quietly turned into one of the market’s stronger recovery stories, with the stock up roughly 80% this year and about 16% over the past 3 months. See our latest analysis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592953752?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-12-17 05:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592953752","market":"us","top_or_hot":-1,"title":"Elanco Animal Health (ELAN): Assessing Valuation After a Strong Share Price Recovery","media":"Simply Wall St.","content":"<div>\n<p>Elanco Animal Health (ELAN) has quietly turned into one of the market’s stronger recovery stories, with the stock up roughly 80% this year and about 16% over the past 3 months. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-assessing-valuation-after-a-strong\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elanco Animal Health (ELAN): Assessing Valuation After a Strong Share Price Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElanco Animal Health (ELAN): Assessing Valuation After a Strong Share Price Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-assessing-valuation-after-a-strong><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elanco Animal Health (ELAN) has quietly turned into one of the market’s stronger recovery stories, with the stock up roughly 80% this year and about 16% over the past 3 months. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-assessing-valuation-after-a-strong\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAN","symbol_name":"Elanco Animal Health Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-assessing-valuation-after-a-strong","article_id":"2592953752","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-assessing-valuation-after-a-strong","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592953752","pubTimestamp":1765919945,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Elanco Animal Health (ELAN) has quietly turned into one of the market’s stronger recovery stories, with the stock up roughly 80% this year and about 16% over the past 3 months.\nSee our latest analysis for Elanco Animal Health.\nAt around $21.70 per share, Elanco’s strong year to date share price return suggests investors are warming to its improving growth profile, even though the five year total shareholder return still shows how deep the earlier drawdown was.\nIf Elanco’s rebound has you...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELAN":"Elanco Animal Health Inc","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4007":"制药","BK4561":"索罗斯持仓"},"translate_title":"Elanco Animal Health(ELAN)：股价强劲复苏后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":1.5},"content_text":"Elanco Animal Health (ELAN) has quietly turned into one of the market’s stronger recovery stories, with the stock up roughly 80% this year and about 16% over the past 3 months. See our latest analysis for Elanco Animal Health. At around $21.70 per share, Elanco’s strong year to date share price return suggests investors are warming to its improving growth profile, even though the five year total shareholder return still shows how deep the earlier drawdown was. If Elanco’s rebound has you rethinking the sector, it could be worth exploring other opportunities across healthcare stocks to see which names share similar momentum with stronger long term track records. With earnings rebounding, revenue creeping higher, and the shares still trading at a meaningful discount to both intrinsic value estimates and analyst targets, is Elanco a genuine value opportunity, or is the market already pricing in its next leg of growth? Most Popular Narrative: 10.2% Undervalued With Elanco last closing at $21.70 against a narrative fair value near $24.17, the story centers on whether higher growth and margins are sustainable.  The fair value estimate has risen slightly to approximately $24.17 from about $24.08, reflecting modestly higher long term growth expectations. The future P/E has ticked up modestly from about 41.62x to approximately 41.77x, suggesting a small increase in the implied valuation multiple.  Read the complete narrative. Curious why a mid cap animal health company commands a valuation multiple usually reserved for market darlings, and what growth blueprint underpins that confidence? The narrative leans heavily on accelerating revenue from new launches, improving margins, and a long runway of earnings power that is anything but conservative. Want to see which profit assumptions line up with that higher fair value, and how long they are expected to hold? Dive in to unpack the full logic behind this pricing story. Result: Fair Value of $24.17 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, execution risk around new product uptake and lingering FX headwinds could quickly challenge the upbeat growth and margin assumptions embedded in today’s valuation. Find out about the key risks to this Elanco Animal Health narrative.  Build Your Own Elanco Animal Health Narrative If you would rather interrogate the numbers yourself and draw your own conclusions, you can build a personalized Elanco thesis in just minutes, Do it your way. A great starting point for your Elanco Animal Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? Before you move on, consider scanning focused stock lists on Simply Wall St that many investors overlook until it is too late.  Accelerate your search for potentially mispriced opportunities with these 913 undervalued stocks based on cash flows that combine strong cash flows with attractive entry points. Explore companies involved in digital infrastructure by reviewing these 80 cryptocurrency and blockchain stocks positioned at the intersection of finance and blockchain innovation. Seek to strengthen your income stream through these 13 dividend stocks with yields > 3% offering yields above 3 percent backed by solid business fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentValuation is complex, but we're here to simplify it.Discover if Elanco Animal Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592953752","isCrawlerRequest":true}